FindTrial
Sign In

Pepinemab

DRUG3 trials

Sponsors

Children's Oncology Group, Vaccinex Inc., H. Lee Moffitt Cancer Center and Research Institute

Conditions

Alzheimer DiseaseHER2-positive Breast CancerRecurrent Malignant Solid NeoplasmRecurrent OsteosarcomaRefractory Malignant Solid NeoplasmRefractory Osteosarcoma

Phase 1

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
CompletedNCT03320330
Children's Oncology GroupRecurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm +1
Start: 2018-01-31End: 2024-06-30Updated: 2024-07-15
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
CompletedNCT04381468
Vaccinex Inc.Alzheimer Disease
Start: 2021-07-22End: 2024-06-05Updated: 2024-08-22
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
SuspendedNCT05378464
H. Lee Moffitt Cancer Center and Research InstituteHER2-positive Breast Cancer
Start: 2022-05-31End: 2026-12-01Target: 28Updated: 2026-09-15

Related Papers

Targeting SEMA4D/PLXN signaling through reactive glia as a common pathology for the treatment of neurodegenerative disorders
Alzheimer s & Dementia2025-12-01
Results of SIGNAL‐AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of targeting reactive astrocytes with pepinemab, SEMA4D blocking antibody, in people with mild Alzheimer’s dementia
Alzheimer s & Dementia2024-12-012 citations
A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).
Journal of Clinical Oncology2024-06-011 citations
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614)
Pediatric Blood & Cancer2024-03-232 citations
Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).
Journal of Clinical Oncology2023-06-013 citations
SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: Clinical proof of concept in Phase 2 HD study supports ongoing clinical development in Phase 1/2 AD study
Alzheimer s & Dementia2023-06-013 citations
645 Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC)
Regular and Young Investigator Award Abstracts2022-11-01
Plexin-B2 and Semaphorins Do Not Drive Rhabdomyosarcoma Proliferation or Migration
Sarcoma2022-05-063 citations
Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
Cancer Research2019-07-01
Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
Immunology2019-07-01
A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).
Journal of Clinical Oncology2019-05-203 citations
Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy
Cancer Immunology Research2019-02-01